Slide 1: Annual Report 2024 Investor Presentation
Annual Report 2024 Investor Presentation March 20, 2025 C O N F I D E N T I A L | ©©Copyright CopyrightBioPorto BioPorto| | 1
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Highlights for 2024
Highlights for 2024 TOTAL REVENUE (FY 2024) ✓ 34% increase in US NGAL revenue drives revenue growth DKK 36.2 million ✓ Expansion of commercial activities globally to increase demand for NGAL An increase of 17% compared to 2023 products ✓ New global distribution agreement with Beckman Coulter, Inc. s
Slide 4: Achievements in 2024
Achievements in 2024
Slide 5: Strengthening of commercial platform
Strengthening of commercial platform BioPorto’s NGAL presence at 9 out of the • Further expansion of business development top 10 best children’s hospitals in the US and sales staff in US and Europe ✓ Boston Children’s Hospital • Converting NGAL awareness to actual demand ✓ Children’s Hospital Colora
Slide 6: New global partnership with Beckman Coulter for distribution of NGAL tests
New global partnership with Beckman Coulter for distribution of NGAL tests • First step in expansion of distribution agreements which is a cornerstone A global leader in clinical in BioPorto’s commercial strategy for NGAL test products diagnostics, with a history that dates back more than • The agre
Slide 7: Enrollment of patients for adult ProNephro AKI (NGAL) commenced in October 2024
Enrollment of patients for adult ProNephro AKI (NGAL) commenced in October 2024 • First patient for adult usage of ProNephro AKI (NGAL) enrolled in October 2024 at Massachusetts General Hospital – well ahead of original schedule • First study will determine cut-off for risk stratification of moderat
Slide 8: Financial results 2024
Financial results 2024
Slide 9: Solid revenue growth in 2024 driven by US NGAL sales
Solid revenue growth in 2024 driven by US NGAL sales Revenue FY 2024, DKKm Revenue per quarter, DKKm +17% +5.1m US NGAL +34% 9.5 9.2 9.7 +11% 36.2 8.6 ROW NGAL 8.0 7.7 7.8 31.0 +24% +4.4m 6.6 23.1 +1% 18.7 +0.2m 10.6 10.8 +33% +0.6m 1.8 2.4 Total NGAL Test Antibodies Others Q1 Q2 Q3 Q4 2023 2024 202
Slide 10: Adjusted EBITDA as per revised guidance Jan 6, 2025
Adjusted EBITDA as per revised guidance Jan 6, 2025 Adjusted EBITDA loss, DKKm • Adjusted EBITDA loss of DKK 70.6 70.6m in 2024 vs. DKK 56.1m 56.1 in 2023 • EBITDA loss for 2024 in the 19.6 19.5 15.3 16.2 middle of the revised guidance of DKK 68-73m as communicated January 6, 2025 FY 2023 Q1 Q2 Q3 Q
Slide 11: Strategic roadmap and milestones towards 2029
Strategic roadmap and milestones towards 2029
Slide 12: Strategic milestones towards 2029
Strategic milestones towards 2029 Targets for 2025-2026 Targets for 2027-2029 Building commercial platform: Key objectives : • Accomplish commercial launch of NGAL test in the US and drive usage • Commercialization of ProNephro AKI pediatrics/young adults (US) (NGAL) for Adult use in US • Consolidat
Slide 13: Important future milestones
Important future milestones Fundraising to fund First patient US First patient US Last patient US FDA submission Exp. US clearance FDA clearance process enrollment for enrollment for enrollment for of ProNephro for ProNephro AKI for ProNephro AKI adult study adult study adult study AKI (NGAL) for (N
Slide 14: Closing of second funding round in H1 2025
Closing of second funding round in H1 2025 • On June 18, BioPorto successfully completed the first funding round • An oversubscribed direct issuance of 50 million new shares with gross proceeds of USD 11.7 million (DKK 81.4 million) • The target for the second funding round is app. USD 8.3 million •
Slide 15: Financial outlook
Financial outlook
Slide 16: 2025 Financial outlook
2025 Financial outlook • Expected revenue growth of 24-66% in 2025 driven by Target total revenue in 2025 Adjusted EBITDA loss in 2025 • Increased sales of NGAL products – primarily in the US • Revenue in 2025 will be back-end loaded • Higher expected adjusted DKK 45-60 DKK 75-85 EBITDA loss in 2025
Slide 17: Aspirations of targeting USD +100 million revenue in 2029
Aspirations of targeting USD +100 million revenue in 2029 Until 2026 • Total revenue of DKK 80-125m by • Revenue: DKK +700m (USD +100m) expanding ProNephro AKI (NGAL) sales • Increasing profitability Revenue Adjusted EBITDA trendline • Cash flow positive • Cash flow positive & EBITDA neutral by end
Slide 18: Q&A Contact
Q&A Contact Niels H. Nielsen, CFO – nhn@bioporto.com Hanne S. Foss, Head of Investor Relations – hsf@bioporto.com +45 4529 0000 | bioporto.com